DAX+0,18 % EUR/USD+0,03 % Gold-0,07 % Öl (Brent)-2,81 %

LAM wird heute durchstarten..........wieso? - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

weil die US-Investoren erst heute durch eine PR erfahren werden, dass der CEO von LAM auf wallstreetreporter.com interviewt wurde und dieses Interview wird wie eine Bombe einschlagen!

http://biz.yahoo.com/prnews/040426/nym031_1.html

Dieses Interview ist den wenigsten in den USA bekannt. Aber jeder sollte selbst zuhören:

http://www.wallstreetreporter.com/linked/LAMPharmaceutical.html

Highlight:

- Ausbau der Vertriebsnetze
- Aquisitionen von anderen Firmen
- Intensivierung des Engagment in China, Süd/Nordamerika
- Weitere Produkte

Das Interview schlummerte für einige Wochen unentdeckt auf wallstreetreporter.com.

Nun ist die offizielle PR mit dem Hinweis auf das Interview draussen...die Amis werden zuschlagen, gerade nach den eher mauen Kursverläufen der vorigen Woche!!!!

:D DER REBOUND BEGINNT!:D
von nix ne Ahnung und Unsinn labern.

LAM wird durchstarten, ob du es willst oder nicht willst!:D
muss willi da zustimmen.
ziemlich kurzsichtiges hypeversuch von max.
rechen dir mal LAMPs umsaetze, verbindlichkeiten und aktienzahl zusammen, und lass bitte solche aufgeblaehte pushparolen

laecherlich..und die wallstreetreporter ist nicht mit aktien bezahlt gell ? ;-)
Kann vielleicht jemand ins Deutsche übersetzen...

COOL the Brothers along with Tony V, plus others were doing naked off shore shorting they did this to destroy Drizen and company. Joey was always with Tony V at the time. I wouldn`t put it past Joey to help Tony V in the plot to get rid of Drizen like he did. Now Joey scre-ed Tony V and the crap is going to start all over again. Cool your doing it the right way I hope you make your money back and more, nothing better to see this go to the dogs and Joey on Yonge St. looking for hand outs. Go for it COOL


Der sich vorgenommen hat, sein Englisch zu verbessern

:) :)
ich hoffe, dass dieses posting nicht ernst genommen wird, denn ich habe da einen verdacht...

mfg
willinvest
So langsam ist das äussert verdächtig: Schon wieder ein basher der erst seit kurzem registriert ist:
Userinfo

Username: willinvest
Registriert seit: 20.04.2004 [ seit 6 Tagen ]
User ist momentan: Online seit 26.04.2004 14:13:25
Threads: 0
Postings: 6 [ Durchschnittlich 0,9854 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen
Interessen: keine Angaben

Mein Tipp: Verabrede dich doch mit Tony_West und macht einen LAM-Basher-Thread auf. Dort könnt ihr Euch gegenseitig ankotzen:laugh: :laugh:
ich stelle euch mal den Text rein...zum SCHMÖCKERN:D

WSR: For those members of our audience, not familiar with LAM Pharmaceutical Corporation and its history and background, let`s start with a timeline and overview of the organization?

LAMP: LAM Pharmaceutical Corporation is based in Lewiston, New York where its laboratories and head office are located. The Company was established in 1994 and it has focused its research efforts right from its inception, on the development of transdermal delivery technology.

Our technology is called the Ionic Polymer Matrix. As a result of several years of development, we have, basically, a very broad platform, which is suitable for delivery of drugs and therapeutic agents, and also wound healing. After several years of research, we’ve made a conscious business decision to choose one of the two major directions and we have decided to first commercialize our wound healing technology.

It was driven by both our business and market priorities. About two years ago, we received FDA approval for our first wound-healing product called LAM IPM Wound Gel™.

We welcome the opportunity of being on this program at this time because it`s a particularly fortuitous timing for us. Having completed two years of research and receiving FDA approval for our first wound healing product,

we`re now in the position where the Company is entering a new phase of growth. Since the approval two years ago, we have done a very credible job in establishing a market perception of our IPM Wound Gel in what is a very difficult and very mature US market.

We`re now at a point that we are ready to proceed with expanding our distribution in United States. Turning to the international opportunities, we have recently announced a major relationship with the largest Chinese pharmaceutical company, Sinopharm. China represents an outstanding market opportunity for us. We also have established a solid distributor relationship in Central and South America and we`re currently pursuing new relationships in Europe and other regions. So, the point that we want to make is that we have embarked on fairly broad based marketing strategies for our wound healing product and that`s actually only the first stage of the Company`s strategy

Now that we have the distribution and marketing effort for our wound product well underway, we are turning attention to our transdermal delivery system and we will be introducing a number of new products into the market over the next 12 to 18 months.

Our growth is based on, not a single product, but a diversification of products. This strategy is going to bring strong cash flow and lead to profit results, and therefore, enhance the perception of our company in the marketplace.

WSR: We understand you are poised to enter an exciting new growth stage. When we talk a bit about the Company from the standpoint of the technology, give us a sense of the depth of that technology.

LAMP: Our technology, the Ionic Polymer Matrix, is a very unique polymer-based technology platform, which allows for delivery of both drugs and therapeutic agents transdermally, and it allows for either topical delivery, in other words on top of the skin, or delivery going all the way into all the layers of skin and right into systemic delivery.
One of the competitive advantages of our technology is its composition. Unlike many other competing products or delivery technologies that are based on exotic elements or contain exotic elements, our technology, our Matrix, is based on what the FDA calls GAS products, which stands for `Generally Regarded as Safe`.

It means that our product is an incredibly safe technology to apply and it can be applied on any parts of the body.

The second competitive advantage of our technology is the ability to control both time and level of delivery over a prolonged period of time. The third advantage is our ability to deliver through transdermal methodology very large molecules. Many transdermal technologies are limiting in that they cannot deliver large molecules. By IPM being able to do that, it gives us the opportunity to deliver drugs and agents that other technologies have not been able to and thus putting us at the forefront of the transdermal group.
In its natural form, the IPM Ionic Polymer Matrix becomes the wound healing product, which is a very clear and very elegant gel. The main ingredient of the IPM gel is an agent called HA, which is hyaluronic acid, and hyaluronic acid is well known in the scientific circle as a natural wound healing agent.

In fact, it is contained in many parts of the body and the competitive advantage on the HA side of our technology is that our wound healing product contains 10 times more HA concentration than the competing products. So, if you take for a given that HA is an effective wound healing agent and if you take for a fact that our product contains 10 times more HA, it gives you a fair idea of how effective our wound healing product is.

The last advantage of our technology as the wound-healing product is that our LAM IPM Wound Gel has been shown in the field and in various anecdotal and other clinical trials to be able to go through all stages of promoting wound healing.

Typically, when you are treating a serious wound and when you look at other technologies, you generally use up to two or three different products to cause the wound healing to occur because wounds require a different type of application depending on the stage it`s at. With IPM Wound Gel, we can go through all stages of wound healing and thus use only our product.

The advantage of that is unimaginable because there are lot of situations in hospitals and other environments where it is really difficult to predict when to switch from one product to another, which requires a great degree of staff attention and a fair amount of additional labor to watch over these wound healing stages. By using IPM Wound Gel, one can basically go ahead and use the same product in all the stages of wound healing. Moreover, our IPM Wound Gel can treat the most serious wounds you can imagine, whether diabetic ulcers or any other wounds.

So, just to recap, the ability to deliver HA to wound beds using our patented Ionic Polymer Matrix, having 10 times more concentration of the primary wound healing agent than our competition has, and being able to use our product through all stages of wound healing rather multiple products provides us with tremendous competitive advantages and market potential for this product.

WSR: Please give us a sense of the whole market opportunity as a diversified healthcare company? Can you provide us the strategy behind that opportunity as a diversified company, the key points of your strategy for success?

LAMP: Let`s begin with wound healing. We have introduced our first product, which targets hard-to-heal wounds, specifically, diabetic ulcers, venous stasis ulcers, leg ulcers, and similar types of serious wounds. The wound healing technology alone offers us an opportunity for numerous derivatives.

For example, we plan to introduce two new products, Post-Surgical Matrix and Burn Matrix, over the course of 2004. So, we will have a full line of wound healing products rather than a single product.

In terms of how we plan to market these wound healing products, we are going to rely on our relationships in North America, in China, and Central America. We certainly hope that we`ll be able to bring to fruition other regional distribution throughout the world. In fact, we are in discussions with several potential partners, which we believe will bring tangible results this year.

Our next phase of growth will be to introduce other products based on the transdermal delivery technology. In line with our strategy to become a diversified healthcare company, we are, at this point, assessing a number of potential acquisitions with complementary products. This objective will give us a broader revenue base and also is going to enable us to maximize the return on our marketing channels by bringing the complementary products to the existing channels. In other cases, in addition to bringing different products, we also will be able to access the distribution channel of the company that we may acquire.

So, essentially, we have a balanced growth strategy and a vision combined with a solid management team and solid financial backing. We are proceeding with growth on a strong and fundamental basis.

WSR: When we talk about the Company in terms of international efforts and the distribution agreement with China`s largest pharmaceutical firm, walk us through the internal opportunity that you see and the strategy and the focus there that you`ve outlined?

LAMP: First of all, having access to Chinese markets presents an enormous opportunity. As mentioned a couple of minutes ago, the first release of our wound healing product is aiming at hard-to-heal wounds such as diabetic ulcers.

Well, you may find it interesting that 30% of world diabetics live in China today. The other thing that you will find interesting is that China does not have a modern wound healing technology in their medical system and so, to be able to take a modern product and introduce it into a large market such as China is a significant opportunity for us, but it is actually only the beginning.

We have agreed with our partners to conduct a series of trials that will further support the already established efficacy of our product. The opportunity to do the trials on a very broad basis and in a very cost effective manner is going to allow us to obtain additional clinical data at very competitive costs. By way of comparison, the cost of conducting clinical trials in China is estimated at 20% or 30% of the cost in the United States. So, it not only gives us market opportunities, but also it will give us some economies of scale and additional development opportunities.

Our Chinese partners have expressed very intense interest in teaming up with us on some of the other developments I`ve mentioned such as the transdermal drug delivery and also in a later phase moving some of the manufacturing to China, thus increasing our cost effectiveness and putting us in a more competitive position on a worldwide basis.

WSR: Does the Company have the funding in place entering a new growth stage along with the management and the infrastructure to accomplish this mission that you`ve outlined?

LAMP: I`ll answer in two parts. When it comes to a company at our stage, which is poised for aggressive growth, we are continuing to seek additional working capital to implement these initiatives. One of the key accomplishments achieved in 2003 was the significant strengthening of our balance sheet. We have improved our net working capital position, and we are now well positioned to fund the initiatives outlined for 2004.
We have a very strong core management team. The Chief Scientist that heads up the research team has over 20 years experience in relevant fields and has over several dozens of patents under his credit. We have a strong development team that is working with him. We have top-level business people including MBAs and CPAs, that work in our business administration and management team.

When you look at the top group of five, we are looking at probably combined 150 years of experience in business, marketing, research and development, and general business administration. For a young growing company, LAM has a very strong core management team.

WSR: What are the things that should remain paramount in our understanding of LAM Pharmaceutical Corporation and the reasons we should continue to track and follow this company in the near-term and beyond?

LAMP: The Company has focused several years on establishing a very strong base, both in management and in research and development, in marketing, and in product introduction.

[/B]We are poised to growth on many fronts. We are continuing to strengthen distribution channels for our FDA approved wound healing gel including the recently signed distribution agreement in China, and plan to introduce two additional wound healing products in 2004. Moreover, we are exploring opportunities to acquire companies with complementary products. We believe that the marketplace will see the benefit of our efforts over the next year and years to come.[/B]

http://www.wallstreetreporter.com/linked/LAMPharmaceutical.h…

:D
Was habe ich euch vor einigen Stunden gesagt?!:laugh:

LAM STARTET DURCH!:eek: DER REBOUND LÄUFT!:D :eek:
Beeindruckend! WOW! So wie ich es gesagt habe! Der Rebound war heute voll im Gange und die kommende Woche wird noch besser!!!:D

+12%!!!!!!:D
ch stelle euch mal den Text rein...zum SCHMÖCKERN

WSR: For those members of our audience, not familiar with LAM Pharmaceutical Corporation and its history and background, let`s start with a timeline and overview of the organization?

LAMP: LAM Pharmaceutical Corporation is based in Lewiston, New York where its laboratories and head office are located. The Company was established in 1994 and it has focused its research efforts right from its inception, on the development of transdermal delivery technology.

Our technology is called the Ionic Polymer Matrix. As a result of several years of development, we have, basically, a very broad platform, which is suitable for delivery of drugs and therapeutic agents, and also wound healing. After several years of research, we’ve made a conscious business decision to choose one of the two major directions and we have decided to first commercialize our wound healing technology.

It was driven by both our business and market priorities. About two years ago, we received FDA approval for our first wound-healing product called LAM IPM Wound Gel™.

We welcome the opportunity of being on this program at this time because it`s a particularly fortuitous timing for us. Having completed two years of research and receiving FDA approval for our first wound healing product,

we`re now in the position where the Company is entering a new phase of growth. Since the approval two years ago, we have done a very credible job in establishing a market perception of our IPM Wound Gel in what is a very difficult and very mature US market.

We`re now at a point that we are ready to proceed with expanding our distribution in United States. Turning to the international opportunities, we have recently announced a major relationship with the largest Chinese pharmaceutical company, Sinopharm. China represents an outstanding market opportunity for us. We also have established a solid distributor relationship in Central and South America and we`re currently pursuing new relationships in Europe and other regions. So, the point that we want to make is that we have embarked on fairly broad based marketing strategies for our wound healing product and that`s actually only the first stage of the Company`s strategy

Now that we have the distribution and marketing effort for our wound product well underway, we are turning attention to our transdermal delivery system and we will be introducing a number of new products into the market over the next 12 to 18 months.

Our growth is based on, not a single product, but a diversification of products. This strategy is going to bring strong cash flow and lead to profit results, and therefore, enhance the perception of our company in the marketplace.

WSR: We understand you are poised to enter an exciting new growth stage. When we talk a bit about the Company from the standpoint of the technology, give us a sense of the depth of that technology.

LAMP: Our technology, the Ionic Polymer Matrix, is a very unique polymer-based technology platform, which allows for delivery of both drugs and therapeutic agents transdermally, and it allows for either topical delivery, in other words on top of the skin, or delivery going all the way into all the layers of skin and right into systemic delivery.
One of the competitive advantages of our technology is its composition. Unlike many other competing products or delivery technologies that are based on exotic elements or contain exotic elements, our technology, our Matrix, is based on what the FDA calls GAS products, which stands for `Generally Regarded as Safe`.

It means that our product is an incredibly safe technology to apply and it can be applied on any parts of the body.

The second competitive advantage of our technology is the ability to control both time and level of delivery over a prolonged period of time. The third advantage is our ability to deliver through transdermal methodology very large molecules. Many transdermal technologies are limiting in that they cannot deliver large molecules. By IPM being able to do that, it gives us the opportunity to deliver drugs and agents that other technologies have not been able to and thus putting us at the forefront of the transdermal group.
In its natural form, the IPM Ionic Polymer Matrix becomes the wound healing product, which is a very clear and very elegant gel. The main ingredient of the IPM gel is an agent called HA, which is hyaluronic acid, and hyaluronic acid is well known in the scientific circle as a natural wound healing agent.

In fact, it is contained in many parts of the body and the competitive advantage on the HA side of our technology is that our wound healing product contains 10 times more HA concentration than the competing products. So, if you take for a given that HA is an effective wound healing agent and if you take for a fact that our product contains 10 times more HA, it gives you a fair idea of how effective our wound healing product is.

The last advantage of our technology as the wound-healing product is that our LAM IPM Wound Gel has been shown in the field and in various anecdotal and other clinical trials to be able to go through all stages of promoting wound healing.

Typically, when you are treating a serious wound and when you look at other technologies, you generally use up to two or three different products to cause the wound healing to occur because wounds require a different type of application depending on the stage it`s at. With IPM Wound Gel, we can go through all stages of wound healing and thus use only our product.

The advantage of that is unimaginable because there are lot of situations in hospitals and other environments where it is really difficult to predict when to switch from one product to another, which requires a great degree of staff attention and a fair amount of additional labor to watch over these wound healing stages. By using IPM Wound Gel, one can basically go ahead and use the same product in all the stages of wound healing. Moreover, our IPM Wound Gel can treat the most serious wounds you can imagine, whether diabetic ulcers or any other wounds.

So, just to recap, the ability to deliver HA to wound beds using our patented Ionic Polymer Matrix, having 10 times more concentration of the primary wound healing agent than our competition has, and being able to use our product through all stages of wound healing rather multiple products provides us with tremendous competitive advantages and market potential for this product.

WSR: Please give us a sense of the whole market opportunity as a diversified healthcare company? Can you provide us the strategy behind that opportunity as a diversified company, the key points of your strategy for success?

LAMP: Let`s begin with wound healing. We have introduced our first product, which targets hard-to-heal wounds, specifically, diabetic ulcers, venous stasis ulcers, leg ulcers, and similar types of serious wounds. The wound healing technology alone offers us an opportunity for numerous derivatives.

For example, we plan to introduce two new products, Post-Surgical Matrix and Burn Matrix, over the course of 2004. So, we will have a full line of wound healing products rather than a single product.

In terms of how we plan to market these wound healing products, we are going to rely on our relationships in North America, in China, and Central America. We certainly hope that we`ll be able to bring to fruition other regional distribution throughout the world. In fact, we are in discussions with several potential partners, which we believe will bring tangible results this year.

Our next phase of growth will be to introduce other products based on the transdermal delivery technology. In line with our strategy to become a diversified healthcare company, we are, at this point, assessing a number of potential acquisitions with complementary products. This objective will give us a broader revenue base and also is going to enable us to maximize the return on our marketing channels by bringing the complementary products to the existing channels. In other cases, in addition to bringing different products, we also will be able to access the distribution channel of the company that we may acquire.

So, essentially, we have a balanced growth strategy and a vision combined with a solid management team and solid financial backing. We are proceeding with growth on a strong and fundamental basis.

WSR: When we talk about the Company in terms of international efforts and the distribution agreement with China`s largest pharmaceutical firm, walk us through the internal opportunity that you see and the strategy and the focus there that you`ve outlined?

LAMP: First of all, having access to Chinese markets presents an enormous opportunity. As mentioned a couple of minutes ago, the first release of our wound healing product is aiming at hard-to-heal wounds such as diabetic ulcers.

Well, you may find it interesting that 30% of world diabetics live in China today. The other thing that you will find interesting is that China does not have a modern wound healing technology in their medical system and so, to be able to take a modern product and introduce it into a large market such as China is a significant opportunity for us, but it is actually only the beginning.

We have agreed with our partners to conduct a series of trials that will further support the already established efficacy of our product. The opportunity to do the trials on a very broad basis and in a very cost effective manner is going to allow us to obtain additional clinical data at very competitive costs. By way of comparison, the cost of conducting clinical trials in China is estimated at 20% or 30% of the cost in the United States. So, it not only gives us market opportunities, but also it will give us some economies of scale and additional development opportunities.

Our Chinese partners have expressed very intense interest in teaming up with us on some of the other developments I`ve mentioned such as the transdermal drug delivery and also in a later phase moving some of the manufacturing to China, thus increasing our cost effectiveness and putting us in a more competitive position on a worldwide basis.

WSR: Does the Company have the funding in place entering a new growth stage along with the management and the infrastructure to accomplish this mission that you`ve outlined?

LAMP: I`ll answer in two parts. When it comes to a company at our stage, which is poised for aggressive growth, we are continuing to seek additional working capital to implement these initiatives. One of the key accomplishments achieved in 2003 was the significant strengthening of our balance sheet. We have improved our net working capital position, and we are now well positioned to fund the initiatives outlined for 2004.
We have a very strong core management team. The Chief Scientist that heads up the research team has over 20 years experience in relevant fields and has over several dozens of patents under his credit. We have a strong development team that is working with him. We have top-level business people including MBAs and CPAs, that work in our business administration and management team.

When you look at the top group of five, we are looking at probably combined 150 years of experience in business, marketing, research and development, and general business administration. For a young growing company, LAM has a very strong core management team.

WSR: What are the things that should remain paramount in our understanding of LAM Pharmaceutical Corporation and the reasons we should continue to track and follow this company in the near-term and beyond?

LAMP: The Company has focused several years on establishing a very strong base, both in management and in research and development, in marketing, and in product introduction.

We are poised to growth on many fronts. We are continuing to strengthen distribution channels for our FDA approved wound healing gel including the recently signed distribution agreement in China, and plan to introduce two additional wound healing products in 2004. Moreover, we are exploring opportunities to acquire companies with complementary products. We believe that the marketplace will see the benefit of our efforts over the next year and years to come.

http://www.wallstreetreporter.com/linked/LAMPharmaceutical.h…
04/27/2004 (07:03 ET) LAMP: Secures $1.2M Additional Financing; Settles Claims - Knobias
04/27/2004 (06:15 ET) LAM Pharmaceutical Announces Additional Financing and Settlement of Legal Claim - PR Newswire
04/26/2004 (06:15 ET) LAM Pharmaceutical CEO Interviewed by Wall Street Reporter - PR Newswire
04/22/2004 (14:15 ET) LAMP: Volume Spike; 42% > 20-adsv, Stock -12.90% - Knobias
04/21/2004 (09:41 ET) TheSUBWAY.com Posts Stock Watch List: Decisive Actions of the Fed! - Market Wire

JS200


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.